Defective Breast Mesh, Acellular Dermal Matrix (ADM), and Bioabsorbable Scaffold Injury Attorneys in New Jersey: The Complete Guide for Women, Families, and Survivors

The journey of a breast cancer survivor or a woman undergoing reconstructive surgery in New Jersey is defined by resilience. Whether you were treated at the Rutgers Cancer Institute of New Jersey in New Brunswick, a major hospital system in Newark or Jersey City, or a private plastic surgery suite in Cherry Hill, you placed your trust in the medical device industry to provide a safe foundation for your recovery. For many women, that foundation was built using acellular dermal matrix (ADM), bioabsorbable scaffolds like GalaFLEX, or synthetic surgical mesh.

We understand that for many New Jersey families, the initial relief of a successful mastectomy or reconstruction has been replaced by a growing sense of alarm. You may be experiencing persistent redness, swelling, or a hardening of the tissue that your doctor cannot fully explain. You may have heard about the Allergan BIOCELL recall or the recent FDA safety communications and wonder if the “internal bra” products used in your body are the reason for your pain. Our team at The Manginello Law Firm, PLLC—operating under the brand Attorney911—is here to provide the clinical depth and legal authority you need to understand what happened and how to move forward.

When you are ready to talk through your situation with an experienced legal team, call us at 1-888-ATTY-911 for a completely free and confidential consultation.

Understanding the Devices: Mesh, ADM, and Scaffolds in Breast Surgery

In the specialized field of New Jersey breast reconstruction and aesthetic surgery, surgeons often use supplemental materials to provide support for an implant or tissue expander. While these products are frequently marketed as a way to achieve a better aesthetic result or a faster recovery, they carry significant risks that were not always fully disclosed to patients.

Acellular Dermal Matrix (ADM) is a biologic graft, usually derived from human or animal skin tissue, that has been processed to remove cells while leaving the structural collagen matrix intact. Common New Jersey brands include AlloDerm (manufactured by Allergan/AbbVie), Strattice, FlexHD (MTF Biologics), and AlloMax (C.R. Bard/Becton Dickinson). Surgeons use these to create a pocket that holds the breast implant in place, acting as a biological “sling.”

Bioabsorbable Scaffolds are synthetic materials designed to be slowly absorbed by your body over 18 to 24 months. The most prominent of these is GalaFLEX, a scaffold made of poly-4-hydroxybutyrate (P4HB). Manufactured by Tepha and Galatea Surgical (acquired by Becton Dickinson), GalaFLEX is often used in New Jersey “internal bra” procedures for mastopexy or breast lift reinforcement.

Synthetic Surgical Mesh, often made of polypropylene, is occasionally used off-label in breast procedures, despite never being designed for the sensitive environment of breast tissue.

Managing Partner Ralph Manginello has spent twenty-seven years holding powerful institutions accountable. Along with Associate Attorney Lupe Peña, our firm brings a technical command of these devices that generalist personal injury firms cannot match. If your reconstruction failed or you developed a serious infection in New Jersey, the type of material used in your body is often the most important piece of evidence in your case.

The New Jersey Legal Landscape: Why Your Case Is Unique

New Jersey holds a unique position in the world of medical device litigation. Not only is the state a global hub for pharmaceutical and medical device manufacturing, but our state law provides specific protections for consumers that do not exist elsewhere.

In the case of Perez v. Wyeth Laboratories, 161 N.J. 1, 734 A.2d 1245 (1999), the New Jersey Supreme Court established a direct-to-consumer advertising exception to the “learned intermediary” doctrine. Usually, manufacturers argue they only have a duty to warn your surgeon, not you. However, in New Jersey, if a manufacturer markets a device—like a textured breast implant or a bioabsorbable scaffold—directly to the public through social media, brochures, or websites, they may be held directly liable for failing to warn the patient of the risks.

For many women in Newark, Jersey City, and Paterson, this legal doctrine is a vital tool. Our associate attorney, Lupe Peña, brings a significant advantage to our clients by combining her experience in insurance defense with her fluent Spanish-language skills. We understand how the other side evaluates these cases in New Jersey and we ensure that every client can communicate directly with their lawyer in the language they speak at home. If you have questions about how New Jersey law protects you, call us at 1-888-ATTY-911.

The FDA Regulatory Failure: The 510(k) Pathway and “Predicate Creep”

A common misconception among New Jersey patients is that the FDA “approved” their breast mesh or scaffold for safety. The reality is far more concerning. Most of these products reached the market through the FDA’s 510(k) clearance pathway. Under 21 USC §360c and 21 CFR Part 807, a device only needs to show it is “substantially equivalent” to a product already on the market.

This has led to a phenomenon known as “predicate creep.” For example, the GalaFLEX mesh used in New Jersey breast lifts was cleared by the FDA because the manufacturer claimed it was similar to a surgical suture. A suture used for a small incision is fundamentally different from a large mesh scaffold intended to support the entire weight of a breast implant, yet the 510(k) system allowed it to pass without the rigorous clinical trials required for Premarket Approval (PMA) under 21 CFR Part 814.

In a landmark November 9, 2023 letter to health care providers, the FDA explicitly stated: “The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.” This admission is the foundation for many New Jersey lawsuits. We use this regulatory record to show that manufacturers marketed these devices for breast surgery while knowing they lacked the clinical evidence to back up their safety claims.

Complications: From Red Breast Syndrome to BIA-ALCL

When these devices fail, the results are often catastrophic for a woman’s health and self-image. We represent New Jersey women who have suffered through a wide spectrum of device-related injuries:

Red Breast Syndrome (RBS) and Endotoxin Science

Red Breast Syndrome is a noninfectious, sterile inflammatory reaction specific to acellular dermal matrix. The skin over the reconstruction area becomes bright red, often mimicking an infection. Research has shown this is caused by bacterial endotoxins—lipopolysaccharides from bacterial cell walls—that remain on the ADM even after sterilization. Brands like FlexHD and AlloMax have been named in FDA communications for significantly higher rates of these complications.

BIA-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma

New Jersey is currently the center of the national litigation regarding BIA-ALCL. This is a CD30-positive, ALK-negative T-cell lymphoma that develops in the scar tissue (capsule) around textured breast implants. The World Health Organization recognized it as a distinct malignancy in 2016. The Allergan BIOCELL recall of July 2019 was triggered by the high incidence of BIA-ALCL in these specific textured products.

Bioabsorbable Scaffold Failures

We are also investigating cases involving GalaFLEX and other P4HB scaffolds that fail to resorb on the manufacturer’s 18-to-24-month timeline. For some New Jersey women, the scaffold remains palpable, causes chronic nerve pain, or leads to significant “bottoming out” where the breast tissue sags prematurely as the scaffold degrades inconsistently.

Ralph Manginello and our team are deeply involved in analyzing These clinical failure modes. We look at the pathology, the 21 CFR §803 Medical Device Reporting (MDR) data, and your specific operative reports to build a case centered on the failure of the technology. Call us at 1-888-288-9911 for a free evaluation of your medical records.

The Allergan MDL 2921 and the Newark Federal Court

New Jersey is the home of the consolidated federal litigation for textured breast implants. In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, MDL No. 2921, is currently proceeding before Judge Brian R. Martinotti in the United States District Court for the District of New Jersey in Newark.

The bellwether trial for this MDL is currently scheduled for October 19, 2026. This trial will be a pivotal moment for thousands of women, and because the court is located in Newark, New Jersey patients have a direct connection to the heart of the national case. Our firm’s admission to federal court and our experience in high-stakes litigation, such as our lead counsel role in the $10,000,000 Bermudez v. Pi Kappa Phi case, demonstrates our capability to handle the corporate giants of the medical device world.

Why Your New Jersey Medical Records Are the Key to Your Case

To file a successful lawsuit in New Jersey, we must identify the specific brand and lot number of the material used in your surgery. Many women are told they have “mesh” or “the internal bra,” but they are not given the specific product names.

1. Request Your Operative Report: This is the most important document. It provides a play-by-play of your surgery.
2. Look for Device Stickers: Hospitals are required to keep “implant logs” that contain stickers with the Unique Device Identifier (UDI) and lot numbers.
3. Pathology Slides: If you had a second surgery to remove the mesh or a biopsy for BIA-ALCL, the pathology slides from the lab are Tier 1 evidence of the tissue’s reaction to the device.

Lupe Peña and Ralph Manginello have the investigative experience to help New Jersey clients secure these records. We know that hospitals can be slow to respond to individual requests; we use the weight of the firm to ensure your records are preserved before the statute of limitations expires.

The Statutes of Limitations in New Jersey

In New Jersey, a person generally has two years from the date of the injury to file a product liability lawsuit. However, the “Discovery Rule” is often critical in medical device cases. Many women do not realize their mesh is the cause of their pain until they see an FDA news report or a whistleblower disclosure, like the one from Dr. Hooman Noorchashm regarding Becton Dickinson’s GalaFLEX marketing.

Even if your original surgery was five or six years ago, you may still have a viable claim if your “discovery” of the injury’s link to the device happened more recently. Waiting too long, however, can result in your claim being permanently barred. This is why immediate consultation at 1-888-ATTY-911 is so important.

A Legacy of Institutional Accountability: Attorney911

At Attorney911, we don’t just handle cases; we fight for systemic change. In November 2025, Ralph Manginello and Lupe Peña filed Bermudez v. Pi Kappa Phi, a $10,000,000 lawsuit that named thirteen defendants, including a major university. That case, which resulted in the shutdown of the fraternity chapter involved, proves our ability to prosecute multi-defendant, complex institutional liability cases.

Medical device manufacturers like Allergan, Becton Dickinson, and MTF Biologics are massive corporations with teams of defense lawyers. You deserve a firm with 27 years of experience that has earned an Avvo “Excellent” 8.2 rating and Martindale-Hubbell Preeminent status. We have recovered over $50 million for our clients because we do not blink when facing large corporate defendants.

Common Questions for New Jersey Patients

Is the “internal bra” safe?

The FDA has stated that the safety of surgical mesh—the material used for the “internal bra”—has not been determined for use in breast surgery. Many New Jersey women have experienced complications like severe infection, reconstruction failure, and chronic pain because these devices were used off-label.

What if I had my surgery at a major center like Rutgers or Hackensack Meridian?

The reputation of the hospital does not protect the manufacturer of a defective device. Even the best surgeons in New Jersey were often misled by the aggressive off-label marketing of brands like GalaFLEX and Phasix.

How much does it cost to hire an attorney?

We work on a contingency fee basis. This means we charge no upfront fees, and we only get paid if we recover compensation for you. We assume all the financial risk of the litigation so you can focus on your health.

What is the role of Lupe Peña in my case?

As a fluently bilingual attorney with a background in insurance defense, Lupe Peña provides our clients with two major advantages. She understands exactly how insurance companies try to devalue your claim, and she ensures that our Spanish-speaking clients have a direct, lawyer-level connection to their case without the need for filters or translators.

Practical Steps to Take Now

If you are in New Jersey and suspect your breast mesh or scaffold is failing:

• Do not delay medical care. Your health is paramount. If you have fever, increasing redness, or a palpable mass, seek an evaluation from a specialist—possibly a different surgeon for a second opinion.
• Keep everything. If you underwent a removal (explantation), ask your surgeon if the device was preserved. In some cases, we can arrange for an independent laboratory to examine the explanted mesh.
• Call 1-888-ATTY-911. We provide a no-obligation sanctuary where you can tell your story and get an honest legal assessment.

Support Resources for New Jersey Women

If you are struggling with a breast cancer diagnosis or reconstruction failure, you are not alone. New Jersey survivors have access to world-class support networks:

• SHARE Cancer Support: Their LatinaSHARE program provides exceptional bilingual patient navigators and Spanish-language support groups (1-844-275-7427).
• The Rutgers Cancer Institute of New Jersey: As an NCI-Designated Comprehensive Cancer Center, they offer patient navigation and second-opinion clinics.
• FORCE (Facing Our Risk of Cancer Empowered): A vital resource for BRCA1/BRCA2 patients (facingourrisk.org).
• Susan G. Komen Breast Care Helpline: Available at 1-877-465-6636 for clinical navigation.

Commitment to the New Jersey Community

From the shores of the Jersey City waterfront to the medical centers of New Brunswick and the communities of Southern New Jersey, we are dedicated to representing women who were treated like test subjects for unproven medical devices. We are members of the Pro Bono College of the State Bar of Texas, a recognition for lawyers who far exceed the aspirational goals for community service. We bring that same commitment to our work in the New Jersey federal courts.

Ralph Manginello, Lupe Peña, and the entire team at The Manginello Law Firm, PLLC are ready to help you hold the medical device industry accountable. Whether you speak English or Spanish, whether you are a cancer survivor or an aesthetic patient, your case matters to us.

Hablamos español. Llame a Lupe Peña al 1-888-ATTY-911 para una consulta gratuita. No pagará nada a menos que recuperemos una compensación para usted.

Final Thoughts to New Jersey Families

When a product liability injury strikes, specifically one as intimate and traumatic as a failed breast reconstruction or a device-linked cancer, it affects the entire family. Our podcast, Attorney911 on Apple Podcasts and Spotify, frequently examins how the law intersects with these deeply personal medical crises. We believe that an informed client is a powerful client.

You may be feeling overwhelmed by medical bills and the prospect of more surgery. We are here to lift that burden. We will handle the 21 CFR §803 reporting, the MDL 2921 filings, and the expert coordination. You have fought hard for your health; let us fight for your justice in New Jersey.

Contact The Manginello Law Firm, PLLC today. Call 1-888-ATTY-911 or visiting our contact page at attorney911.com/contact/. We have the experience, the technical knowledge, and the commitment to see your case through to the end.

Attorney Advertising: This content is for educational and informational purposes only and does not constitute legal advice. Past results, including our $10,000,000 filing in Bermudez v. Pi Kappa Phi, do not guarantee future outcomes. Every case is unique. No attorney-client relationship is formed until a written contract is signed. Ralph Manginello is licensed in Texas and admitted to the U.S. District Court for the Southern District of Texas; we work with local counsel in other jurisdictions as required.